Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Aug 1;98(3):863–874. doi: 10.1172/JCI118859

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

J C Reverter 1, S Béguin 1, H Kessels 1, R Kumar 1, H C Hemker 1, B S Coller 1
PMCID: PMC507497  PMID: 8698879

Abstract

The murine/human chimeric monoclonal antibody fragment (c7E3 Fab) blocks GPIIb/IIIa and alpha v beta 3 receptors, inhibits platelet aggregation, and decreases the frequency of ischemic events after coronary artery angioplasty in patients at high risk of suffering such events. Although inhibition of platelet aggregation is likely to be the major mechanism of c7E3 Fab's effects, since activated platelets facilitate thrombin generation, it is possible that c7E3 Fab also decreases thrombin generation. To test this hypothesis, the effects of c7E3 Fab and other antiplatelet agents were tested in a thrombin generation assay triggered by tissue factor. c7E3 Fab produced dose-dependent inhibition of thrombin generation, reaching a plateau of 45-50% inhibition at concentrations > or = 15 micrograms/ml. It also inhibited thrombin-antithrombin complex formation, prothrombin fragment F1-2 generation, platelet-derived growth factor and platelet factor 4 release, incorporation of thrombin into clots, and microparticle formation. Antibody 6D1, which blocks platelet GPIb binding of von Willebrand factor, had no effect on thrombin generation, whereas antibody 10E5, which blocks GPIIb/IIIa but not alpha v beta 3 receptors decreased thrombin generation by approximately 25%. Combining antibody LM609, which blocks alpha v beta 3 receptors, with 10E5 increased the inhibition of thrombin generation to approximately 32-41%. The platelets from three patients with Glanzmann thrombasthenia, who lacked GPIIb/IIIa receptors but had normal or increased alpha v beta 3 receptors, supported approximately 21% less thrombin generation than normal platelets. We conclude that thrombin generation initiated by tissue factor in the presence of platelets is significantly inhibited by c7E3 Fab, most likely in part through both GPIIb/IIIa and alpha v beta 3 blockade, and that this effect may contribute to its antithrombotic properties.

Full Text

The Full Text of this article is available as a PDF (231.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson H. V. Restenosis after coronary angioplasty. Dis Mon. 1993 Sep;39(9):613–670. doi: 10.1016/0011-5029(93)90002-k. [DOI] [PubMed] [Google Scholar]
  2. Andreotti F., Davies G. J., Ujang S. B., Sritara P., Kluft C., Maseri A. High-dose aspirin, thrombin, and coronary angioplasty. Lancet. 1993 May 1;341(8853):1161–1161. [PubMed] [Google Scholar]
  3. Baruch D., Hemker H. C., Lindhout T. Kinetics of thrombin-induced release and activation of platelet factor V. Eur J Biochem. 1986 Jan 2;154(1):213–218. doi: 10.1111/j.1432-1033.1986.tb09381.x. [DOI] [PubMed] [Google Scholar]
  4. Basic-Micic M., Roman C., Herpel U., Kling E., Scholz B., Breddin H. K. Platelet-induced thrombin generation time: a new sensitive global assay for platelet function and coagulation. Method and first results. Haemostasis. 1992;22(6):309–321. doi: 10.1159/000216341. [DOI] [PubMed] [Google Scholar]
  5. Beer J. H., Springer K. T., Coller B. S. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood. 1992 Jan 1;79(1):117–128. [PubMed] [Google Scholar]
  6. Bevers E. M., Comfurius P., Nieuwenhuis H. K., Levy-Toledano S., Enouf J., Belluci S., Caen J. P., Zwaal R. F. Platelet prothrombin converting activity in hereditary disorders of platelet function. Br J Haematol. 1986 Jun;63(2):335–345. doi: 10.1111/j.1365-2141.1986.tb05557.x. [DOI] [PubMed] [Google Scholar]
  7. Bevers E. M., Comfurius P., Zwaal R. F. Mechanisms involved in platelet procoagulant response. Adv Exp Med Biol. 1993;344:195–207. doi: 10.1007/978-1-4615-2994-1_15. [DOI] [PubMed] [Google Scholar]
  8. Bevers E. M., Comfurius P., Zwaal R. F. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev. 1991 Sep;5(3):146–154. doi: 10.1016/0268-960x(91)90031-7. [DOI] [PubMed] [Google Scholar]
  9. Bevers E. M., Comfurius P., van Rijn J. L., Hemker H. C., Zwaal R. F. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982 Feb;122(2):429–436. doi: 10.1111/j.1432-1033.1982.tb05898.x. [DOI] [PubMed] [Google Scholar]
  10. Béguin S., Kessels H., Dol F., Hemker H. C. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. Thromb Haemost. 1992 Aug 3;68(2):136–142. [PubMed] [Google Scholar]
  11. Béguin S., Lindhout T., Hemker H. C. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost. 1989 Feb 28;61(1):25–29. [PubMed] [Google Scholar]
  12. Cadroy Y., Hanson S. R., Kelly A. B., Marzec U. M., Evatt B. L., Kunicki T. J., Montgomery R. R., Harker L. A. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood. 1994 Jun 1;83(11):3218–3224. [PubMed] [Google Scholar]
  13. Carr M. E., Jr, Carr S. L., Hantgan R. R., Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost. 1995 Mar;73(3):499–505. [PubMed] [Google Scholar]
  14. Cheresh D. A., Spiro R. C. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987 Dec 25;262(36):17703–17711. [PubMed] [Google Scholar]
  15. Cohen I., Burk D. L., White J. G. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb-IIIa complex on the development of clot tension. Blood. 1989 May 15;73(7):1880–1887. [PubMed] [Google Scholar]
  16. Coller B. S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985 Jul;76(1):101–108. doi: 10.1172/JCI111931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Coller B. S., Anderson K., Weisman H. F. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995 Jul;74(1):302–308. [PubMed] [Google Scholar]
  18. Coller B. S., Beer J. H., Scudder L. E., Steinberg M. H. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood. 1989 Jul;74(1):182–192. [PubMed] [Google Scholar]
  19. Coller B. S., Cheresh D. A., Asch E., Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood. 1991 Jan 1;77(1):75–83. [PubMed] [Google Scholar]
  20. Coller B. S., Peerschke E. I., Scudder L. E., Sullivan C. A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983 Jul;72(1):325–338. doi: 10.1172/JCI110973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Coller B. S., Peerschke E. I., Scudder L. E., Sullivan C. A. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood. 1983 Jan;61(1):99–110. [PubMed] [Google Scholar]
  22. Coller B. S., Scudder L. E. Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood. 1985 Dec;66(6):1456–1459. [PubMed] [Google Scholar]
  23. Coller B. S., Springer K. T., Scudder L. E., Kutok J. L., Ceruso M., Prestwich G. D. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. J Biol Chem. 1993 Oct 5;268(28):20741–20743. [PubMed] [Google Scholar]
  24. Fox J. E., Austin C. D., Reynolds C. C., Steffen P. K. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem. 1991 Jul 15;266(20):13289–13295. [PubMed] [Google Scholar]
  25. Gemmell C. H., Sefton M. V., Yeo E. L. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem. 1993 Jul 15;268(20):14586–14589. [PubMed] [Google Scholar]
  26. Gretch D. R., Suter M., Stinski M. F. The use of biotinylated monoclonal antibodies and streptavidin affinity chromatography to isolate herpesvirus hydrophobic proteins or glycoproteins. Anal Biochem. 1987 May 15;163(1):270–277. doi: 10.1016/0003-2697(87)90123-0. [DOI] [PubMed] [Google Scholar]
  27. HARDISTY R. M., DORMANDY K. M., HUTTON R. A. THROMBASTHENIA. STUDIES ON THREE CASES. Br J Haematol. 1964 Jul;10:371–387. doi: 10.1111/j.1365-2141.1964.tb00714.x. [DOI] [PubMed] [Google Scholar]
  28. Hampton K. K., Cerletti C., Loizou L. A., Bucchi F., Donati M. B., Davies J. A., de Gaetano G., Prentice C. R. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. Thromb Haemost. 1990 Aug 13;64(1):17–20. [PubMed] [Google Scholar]
  29. Hemker H. C., Wielders S., Kessels H., Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost. 1993 Oct 18;70(4):617–624. [PubMed] [Google Scholar]
  30. Hemker H. C., Willems G. M., Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost. 1986 Aug 20;56(1):9–17. [PubMed] [Google Scholar]
  31. Hoffman M., Monroe D. M., Roberts H. R. Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb Haemost. 1992 Jul 6;68(1):74–78. [PubMed] [Google Scholar]
  32. Hultin M. B. Modulation of thrombin-mediated activation of factor VIII:C by calcium ions, phospholipid, and platelets. Blood. 1985 Jul;66(1):53–58. [PubMed] [Google Scholar]
  33. Kessels H., Béguin S., Andree H., Hemker H. C. Measurement of thrombin generation in whole blood--the effect of heparin and aspirin. Thromb Haemost. 1994 Jul;72(1):78–83. [PubMed] [Google Scholar]
  34. Kohmura C., Gold H. K., Yasuda T., Holt R., Nedelman M. A., Guerrero J. L., Weisman H. F., Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb. 1993 Dec;13(12):1837–1842. doi: 10.1161/01.atv.13.12.1837. [DOI] [PubMed] [Google Scholar]
  35. Kyrle P. A., Westwick J., Scully M. F., Kakkar V. V., Lewis G. P. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man--effect of low-dose aspirin. Thromb Haemost. 1987 Feb 3;57(1):62–66. [PubMed] [Google Scholar]
  36. Majerus P. W., Miletich J. P. Relationships between platelets and coagulation factors in hemostasis. Annu Rev Med. 1978;29:41–49. doi: 10.1146/annurev.me.29.020178.000353. [DOI] [PubMed] [Google Scholar]
  37. McNamara C. A., Sarembock I. J., Gimple L. W., Fenton J. W., 2nd, Coughlin S. R., Owens G. K. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993 Jan;91(1):94–98. doi: 10.1172/JCI116206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Moliterno D. J., Califf R. M., Aguirre F. V., Anderson K., Sigmon K. N., Weisman H. F., Topol E. J. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol. 1995 Mar 15;75(8):559–562. doi: 10.1016/s0002-9149(99)80616-x. [DOI] [PubMed] [Google Scholar]
  39. Moorehead M. T., Westengard J. C., Bull B. S. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg. 1984 Apr;63(4):394–398. [PubMed] [Google Scholar]
  40. Nesheim M. E., Furmaniak-Kazmierczak E., Henin C., Côté G. On the existence of platelet receptors for factor V(a) and factor VIII(a). Thromb Haemost. 1993 Jul 1;70(1):80–86. [PubMed] [Google Scholar]
  41. Neuenschwander P., Jesty J. A comparison of phospholipid and platelets in the activation of human factor VIII by thrombin and factor Xa, and in the activation of factor X. Blood. 1988 Nov;72(5):1761–1770. [PubMed] [Google Scholar]
  42. Newman P. J., Allen R. W., Kahn R. A., Kunicki T. J. Quantitation of membrane glycoprotein IIIa on intact human platelets using the monoclonal antibody, AP-3. Blood. 1985 Jan;65(1):227–232. [PubMed] [Google Scholar]
  43. Nomura S., Komiyama Y., Murakami T., Funatsu A., Kokawa T., Sugo T., Matsuda M., Yasunaga K. Flow cytometric analysis of surface membrane proteins on activated platelets and platelet-derived microparticles from healthy and thrombasthenic individuals. Int J Hematol. 1993 Oct;58(3):203–212. [PubMed] [Google Scholar]
  44. Osterud B., Rapaport S. I., Lavine K. K. Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator. Blood. 1977 May;49(5):819–834. [PubMed] [Google Scholar]
  45. Rawala-Sheikh R., Ahmad S. S., Ashby B., Walsh P. N. Kinetics of coagulation factor X activation by platelet-bound factor IXa. Biochemistry. 1990 Mar 13;29(10):2606–2611. doi: 10.1021/bi00462a025. [DOI] [PubMed] [Google Scholar]
  46. Reed G. L., Matsueda G. R., Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin. Thromb Haemost. 1992 Sep 7;68(3):315–320. [PubMed] [Google Scholar]
  47. Sandberg H., Andersson L. O., Höglund S. Isolation and characterization of lipid-protein particles containing platelet factor 3 released from human platelets. Biochem J. 1982 Apr 1;203(1):303–311. doi: 10.1042/bj2030303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sims P. J., Faioni E. M., Wiedmer T., Shattil S. J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem. 1988 Dec 5;263(34):18205–18212. [PubMed] [Google Scholar]
  49. Sims P. J., Wiedmer T., Esmon C. T., Weiss H. J., Shattil S. J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem. 1989 Oct 15;264(29):17049–17057. [PubMed] [Google Scholar]
  50. Swords N. A., Tracy P. B., Mann K. G. Intact platelet membranes, not platelet-released microvesicles, support the procoagulant activity of adherent platelets. Arterioscler Thromb. 1993 Nov;13(11):1613–1622. doi: 10.1161/01.atv.13.11.1613. [DOI] [PubMed] [Google Scholar]
  51. Szczeklik A., Krzanowski M., Góra P., Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992 Oct 15;80(8):2006–2011. [PubMed] [Google Scholar]
  52. Thiagarajan P., Tait J. F. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem. 1990 Oct 15;265(29):17420–17423. [PubMed] [Google Scholar]
  53. Topol E. J., Califf R. M., Weisman H. F., Ellis S. G., Tcheng J. E., Worley S., Ivanhoe R., George B. S., Fintel D., Weston M. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet. 1994 Apr 9;343(8902):881–886. doi: 10.1016/s0140-6736(94)90007-8. [DOI] [PubMed] [Google Scholar]
  54. Tracy P. B., Nesheim M. E., Mann K. G. Proteolytic alterations of factor Va bound to platelets. J Biol Chem. 1983 Jan 10;258(1):662–669. [PubMed] [Google Scholar]
  55. Tsujinaka T., Kajiwara Y., Kambayashi J., Sakon M., Higuchi N., Tanaka T., Mori T. Synthesis of a new cell penetrating calpain inhibitor (calpeptin). Biochem Biophys Res Commun. 1988 Jun 30;153(3):1201–1208. doi: 10.1016/s0006-291x(88)81355-x. [DOI] [PubMed] [Google Scholar]
  56. Weiss H. J., Kochwa S. Studies of platelet function and proteins in 3 patients with Glanzmann's thrombasthenia. J Lab Clin Med. 1968 Jan;71(1):153–165. [PubMed] [Google Scholar]
  57. Weiss H. J., Lages B. Studies of thromboxane B2, platelet factor 4, and fibrinopeptide A in bleeding-time blood of patients deficient in von Willebrand factor, platelet glycoproteins Ib and IIb-IIIa, and storage granules. Blood. 1993 Jul 15;82(2):481–490. [PubMed] [Google Scholar]
  58. Weiss H. J. Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol. 1994 Oct;31(4):312–319. [PubMed] [Google Scholar]
  59. Weiss H. J., Turitto V. T., Baumgartner H. R. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest. 1986 Oct;78(4):1072–1082. doi: 10.1172/JCI112663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Weitz J. I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990 Aug;86(2):385–391. doi: 10.1172/JCI114723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Wyshock E. G., Stewart G. J., Colman R. W. Thrombin-stimulated human platelets express molecular forms of alpha-granule factor V (FV), which differ from FVa. Thromb Haemost. 1994 Dec;72(6):947–956. [PubMed] [Google Scholar]
  62. Yasu T., Oshima S., Imanishi M., Nonogi H., Haze K., Kuramochi M., Omae T., Hayashi Y., Yamamoto S. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. Am J Cardiol. 1993 May 15;71(13):1164–1168. doi: 10.1016/0002-9149(93)90640-x. [DOI] [PubMed] [Google Scholar]
  63. Zucker M. B., Pert J. H., Hilgartner M. W. Platelet function in a patient with thrombasthenia. Blood. 1966 Oct;28(4):524–534. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES